Evaluation of gender in the oral pharmacokinetics of clindamycin in humans
✍ Scribed by Miriam del Carmen Carrasco-Portugal; Miguel Luján; Francisco Javier Flores-Murrieta
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 69 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0142-2782
- DOI
- 10.1002/bdd.624
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Clindamycin is an antimicrobial agent metabolized by CYP3A4. Gender may influence the pharmacokinetics of drugs metabolized by this pathway, however, no information about differences in the pharmacokinetics of clindamycin in men and women is available. The purpose of this study was to evaluate gender differences in clindamycin oral pharmacokinetics. Twenty‐four subjects (11 men and 13 women) received an oral 600 mg dose of clindamycin under fasting conditions and plasma concentrations were obtained at selected times during 12 h. Increased plasma levels were observed in women, but when the dose was normalized by the body weight of individuals, these differences disappeared, indicating that gender does not play an important role in the pharmacokinetics of this drug. Copyright © 2008 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract Pharmacokinetic and bioavailability parameters of propranolol were estimated in 10 healthy adult subjects after single oral doses of two commercial tablet formulations of propranolol hydrochloride (2 × 40 mg). Plasma concentrations of propranolol were determined by a high‐performance li
A single-blind study was conducted in 10 healthy male subjects. Each subject was tested with four single oral doses of capsules containing 25, 50, 100, 200mg almitrine bismesylate and one dose of placebo. Blood samples were drawn as a function of time and the concentration of almitrine in plasma was
## Abstract A comparative bioavailability study was conducted with two capsule formulations of danazol (200 mg) in 16 healthy adult male volunteers. Fasting subjects received single doses (400 mg) of each formulation on separate occasions 1 week apart. Blood samples were drawn at specified times up
The effects of gender on the pharmacokinetics of verapamil and its active metabolite, norverapamil, following single oral dose (80 mg, Isoptin) to 12 healthy male (mean age: 25.75+/-2.42 years, mean body weight: 70.59+/-9.94 kg) and 12 healthy female subjects (mean age: 24.08+/-2.84 years, mean body